<DOC>
	<DOCNO>NCT01002118</DOCNO>
	<brief_summary>Cardiovascular disease mortality large comorbidity within dialysis population . Nearly 50 % hemodialysis patient congestive heart failure initiation . According recent United States Renal Data System ( USRDS ) , 40 % incident dialysis patient cardiovascular event die within first 9 month dialysis . It postulate Omega-3 fatty acid could provide beneficial cardioprotection hemodialysis patient . The investigator propose evaluate Omega-3 fatty acid dose cardiovascular parameter incident hemodialysis population . Initially , pilot study . Ultimately , information use adequately plan large intervention trial use Omega-3 fatty acid incident hemodialysis patient .</brief_summary>
	<brief_title>Feasibility Study Omega-3 Fatty Acids Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Age &gt; 18 year old Initiated dialysis past 3 month Signed informed consent Attending University Iowa dialysis unit duration study Age &gt; 70 Unable provide consent Currently take fish oil supplementation rhythm sinus implantable cardioverterdefibrillator pacemaker myocardial infarction , revascularization unstable angina past 3 month hospitalization past 3 month symptomatic heart failure know leave ventricular ejection fraction &lt; 30 % history significant bleeding disorder severe bleed episode require hospitalization past 3 month ( GI bleed hemorrhagic stroke ) unexplained HgB drop &gt; 2 gm/dl past 3 month chronic warfarin anticoagulation therapy ( Lovenox ) pregnant nurse mother allergic fish , fish oil fish product Participation trial investigational product characteristic determine investigator would make sudy participation inappropriate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>heart rate variability</keyword>
	<keyword>Dialysis</keyword>
</DOC>